Goldman Sachs’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-18,646
Closed -$629K – 6783
2026
Q2
$629K Buy
18,646
+11,464
+160% +$344K ﹤0.01% 5559
2026
Q1
$209K Buy
+7,182
New +$208K ﹤0.01% 6064
2023
Q3
– Sell
-11,730
Closed -$274K – 5694
2023
Q2
$274K Hold
11,730
– – ﹤0.01% 5055
2023
Q1
$273K Sell
11,730
-9,719
-45% -$243K ﹤0.01% 5163
2022
Q4
$540K Buy
21,449
+9,719
+83% +$261K ﹤0.01% 4825
2022
Q3
$310K Sell
11,730
-38,354
-77% -$1.18M ﹤0.01% 5284
2022
Q2
$1.45M Buy
50,084
+38,354
+327% +$1.14M ﹤0.01% 4325
2022
Q1
$404K Hold
11,730
– – ﹤0.01% 5470
2021
Q4
$514K Buy
+11,730
New +$555K ﹤0.01% 5364

Other funds holding IDNA

Goldman Sachs's IDNA Position: Q3 2026 in Review

Goldman Sachs sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2026, closing a stake of 18,646 shares — an estimated $629K sold.

Goldman Sachs first reported a position in IDNA in Q4 2021 and held it in 9 quarters. The position peaked at $1.45M in Q2 2022. 81 funds tracked by Wall St. Rank hold IDNA as of Q3 2026.

  • Goldman Sachs reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2026 after selling out during the quarter.
  • Goldman Sachs sold 18,646 iShares Genomics Immunology and Healthcare ETF shares in Q3 2026, an estimated $629K.
  • Goldman Sachs first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 9 quarters.
  • Goldman Sachs's iShares Genomics Immunology and Healthcare ETF position peaked at $1.45M in Q2 2022.
  • 81 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.